SCIENCE 37
Offerings
SCIENCE 37
Offerings
Science 37 accelerates clinical research and enables a more representative patient participation. We bring a unique combination of our purpose-built technology platform and specialized networks to enable hybrid and decentralized clinical trials, globally.
Science 37 accelerates clinical research and enables a more representative patient participation. We bring a unique combination of our purpose-built technology platform and specialized networks to enable hybrid and decentralized clinical trials, globally.
Eliminate Disconnected Solutions with Unified Technology
The Science 37 Technology Platform delivers the most comprehensive solution in the industry. Our end-to-end SaaS platform enables eConsent, Telemedicine, eSource, and eCOA, creating a unified experience for all users and effectively coordinating clinical research across all settings of care.
Eliminate Disconnected Solutions with Unified Technology
The Science 37 Technology Platform delivers the most comprehensive solution in the industry. Our end-to-end SaaS platform enables eConsent, Telemedicine, eSource, and eCOA, creating a unified experience for all users and effectively coordinating clinical research across all settings of care.
Support Any Study Configuration.
The Science 37 Operating System™ (OS) supports any phase of a study — including pivotal trials or real-world evidence (RWE) studies — for any number of indications. These include oncology, CNS, endocrinology, pediatrics, and infectious and rare diseases.
We’ve successfully supported sponsors from biotech and big pharma and their CROs in enabling greater patient recruitment, at scale, globally.
Support Any Study Configuration.
The Science 37 Operating System™ (OS) supports any phase of a study — including pivotal trials or real-world evidence (RWE) studies — for any number of indications. These include oncology, CNS, endocrinology, pediatrics, and infectious and rare diseases.
We’ve successfully supported sponsors from biotech and big pharma and their CROs in enabling greater patient recruitment, at scale, globally.
Universal Access With Diversity & Inclusion.
The Science 37 OS enables access to patients and providers, leading to faster clinical trial enrollment, greater retention, and a more representative patient population.
Our Diversity in Clinical Trials business unit drives diversity, access, and equity in clinical research. Through hybrid and decentralized clinical trial elements— and inclusive strategies—we enable access to patients and providers anywhere.
Universal Access With Diversity & Inclusion.
The Science 37 OS enables access to patients and providers, leading to faster clinical trial enrollment, greater retention, and a more representative patient population.
Our Diversity in Clinical Trials business unit drives diversity, access, and equity in clinical research. Through hybrid and decentralized clinical trial elements— and inclusive strategies—we enable access to patients and providers anywhere.
Learn Why our Clients Trust Us
[The Science 37] Metasite strategy complements the conventional site mix to accelerate the recruitment of patients in remote locations and in underrepresented communities.
“[The Science 37] Metasite strategy complements the conventional site mix to accelerate the recruitment of patients in remote locations and in underrepresented communities.”
IDC Real-World Evidence, Social Determinants of Health, and Digital Biomarkers in Driving Patient Recruitment, #US50382823, March 2023
Science 37 places a significant emphasis on training. Healthcare staff are trained on the platform used in clinical trials, ensuring that when the patient and provider come into contact during any DCT, the patient experience is easy, and the data collecte
“Science 37 places a significant emphasis on training. Healthcare staff are trained on the platform used in clinical trials, ensuring that when the patient and provider come into contact during any DCT, the patient experience is easy, and the data collected is accurate.”
GlobalData
Science 37 delivers a model that truly supports patient preference—providing access through the site or through a DCT model. The patient’s choice is front and center.
“Science 37 delivers a model that truly supports patient preference—providing access through the site or through a DCT model. The patient’s choice is front and center.”
Clinical Trial Sponsor